TDO2 and Parkinson disease: While increases in Kyn levels would expectedly nullify the effect of TDO inhibition, we believe that local changes in kynurenine pathway metabolite levels, for instance in specific cell types, or brain regions in which IDO1 is not expressed, may underlie the beneficial effects of TDO inhibitor treatment observed in the PD model, although this would require further study.